Susan E. Quaggin, MD, FASN, To Lead American Society of Nephrology in 2021; Looks Ahead To Dramatically Positive Changes In Kidney Care
The American Society of Nephrology (ASN) welcomes Susan E. Quaggin, MD, FRCP(C), FASN, as ASN President, effective January 1, 2021. Dr. Quaggin succeeds Anupam Agarwal, MD, FASN.
5-Jan-2021 11:45 AM EST Add to Favorites
• In a survey of adults with kidney failure who were receiving dialysis, most owned mobile devices and had intermediate or advanced mobile health proficiency.
• The main reasons for using mobile health were for making appointments,...
17-Dec-2020 9:00 AM EST Add to Favorites
• An estimated 375 adult kidney transplant recipients lose their transplant every year due to a lack of coverage of immunosuppressive medications after the prior 36-month Medicare coverage period.
• Congress passes ASN priority legislation to...
22-Dec-2020 8:30 AM EST Add to Favorites
• Exposure to higher amounts of fine particulate air pollution was associated with a greater likelihood of having chronic kidney disease.
• This link was stronger in urban areas, males, younger adults, and adults without comorbid diseases.
11-Dec-2020 8:15 AM EST Add to Favorites
Public Forums Announced to Provide Input to the Joint Task Force to Reassess the Inclusion of Race in Diagnosing Kidney Diseases
A joint statement from the National Kidney Foundation and the American Society of Nephrology
December 17, 2020
17-Dec-2020 8:25 AM EST Add to Favorites
• When determining whether kidneys are suitable for transplantation in the United States, biopsy analyses don’t provide useful information beyond standard donor and recipient characteristics.
• Many kidneys discarded based on biopsy findings...
10-Dec-2020 9:00 AM EST Add to Favorites
• A recent analysis indicates that Accountable Care Organizations may reduce the cost of medical care for patients undergoing dialysis.
• The cost savings were seen only for patients who regularly received care from primary care physicians.
19-Nov-2020 9:00 AM EST Add to Favorites
• The diabetes drug canagliflozin slowed kidney function decline in patients with diabetes and advanced chronic kidney disease.
• The drug also reduced the risk of developing kidney failure and cardiovascular problems in these patients.
13-Nov-2020 10:35 AM EST Add to Favorites
See All News
American Society of Nephrology President and ASN Director of Policy and Government Affairs Comment on Trump Administration’s Overhaul of Kidney Care
10-Jul-2019 9:00 AM EDT
ASN Policy Expert and HIV Patient Advocate Available for Comment on Anticipated Passage of Hope ACT Today
12-Nov-2013 12:00 PM ESTSee All Experts